Table 1. Correlation of VE1 with clinicopathological variables.
| Clinicopathological variables | PTC total, 476 (100.0%) | VE1+, 290 (60.9%) | VE1–, 186 (39.1%) | P |
|---|---|---|---|---|
| Age at diagnosis (yr), mean ± SD | 44.95±16.06 | 47.22±15.83 | 47.22±15.84 | 0.314 |
| <55, n (%) | 319 (67.0) | 186 (58.3) | 133 (41.7) | 0.058 |
| ≥55, n (%) | 157 (33.0) | 104 (66.2) | 53 (33.8) | |
| Sex, n (%) | 0.34 | |||
| Male | 98 (20.6) | 62 (63.3) | 36 (36.7) | |
| Female | 378 (79.4) | 228 (60.3) | 150 (39.7) | |
| Tumor size (cm), mean ± SD | 2.7±1.86 | 2.6±1.78 | 2.87±1.98 | 0.467 |
| ≤1, n (%) | 51 (10.7) | 28 (54.9) | 23 (45.1) | 0.379 |
| >1, n (%) | 403 (84.7) | 250 (62) | 153 (38) | |
| Cannot be determined, n (%) | 22(4.6) | 12 (54.5) | 10 (45.5) | |
| Histological variants, n (%) | <0.0001 | |||
| 1. Classic | 369 (77.3) | 259 (70.2) | 110 (29.8) | |
| 2. Encapsulated | 14 (2.9) | 4 (28.6) | 10 (71.4) | |
| 3. Follicular | 59 (12.4) | 10 (16.9) | 49 (83.1) | |
| Infiltrative | 47 (9.8) | 9 (19.1) | 38 (80.9) | |
| Invasive encapsulated | 12 (2.5) | 1 (8.3) | 11 (91.7) | |
| 4. Diffuse sclerosing | 5 (1.1) | 2 (40.0) | 3 (60.0) | |
| 5. Tall cell | 14 (2.9) | 13 (92.9) | 1 (7.1) | |
| 6. Other† | 15 (3.2) | 2 (13.3) | 13 (86.7) | |
| Multifocality, n (%) | 0.184 | |||
| Absent | 346 (72.7) | 204 (59) | 142 (41) | |
| Present | 99 (20.8) | 64 (64.6) | 35 (35.4) | |
| Cannot be determined | 31 (6.5) | 22 (71.0) | 9 (29.0) | |
| Margin, n (%) | 0.022 | |||
| Negative | 358 (75.2) | 209 (58.4) | 149 (41.6) | |
| Positive | 106 (22.3) | 74 (69.8) | 32 (30.2) | |
| Cannot be determined | 12 (2.5) | 7 (58.3) | 5 (41.7) | |
| Lymphovascular invasion, n (%) | 0.198 | |||
| Absent | 411 (86.3) | 254 (61.8) | 157 (38.2) | |
| Present | 65 (13.7) | 36 (55.4) | 29 (44.6) | |
| Extrathyroidal extension, n (%) | <0.0001 | |||
| Absent | 292 (61.3) | 152 (52.1) | 140 (47.9) | |
| Present | 184 (38.7) | 138 (75.0) | 46 (25.0) | |
| Hashimoto’s thyroiditis, n (%) | 0.009 | |||
| Absent | 451 (94.7) | 281 (62.3) | 170 (37.7) | |
| Present | 25 (5.3) | 9 (36.0) | 16 (64.0) | |
| Lymph node metastasis, n (%) | 0.455 | |||
| Absent (N0) | 37 (7.8) | 24 (64.9) | 13 (35.1) | |
| Present (N1) | 137 (28.8) | 85 (62.0) | 52 (38.0) | |
| Unknown (NX) | 302 (63.4) | 181 (59.9) | 121 (40.1) | |
| Distant metastasis, n (%) | n/a | |||
| Absent | 475 (99.8) | 289 (60.8) | 186 (39.2) | |
| Present | 1 (0.2) | 1 (100.0) | 0 (0.0) | |
| Staging (AJCC 8th edition), n (%) | n/a | |||
| Stage I+II | 461 (96.8) | 279 (60.5) | 182 (39.5) | |
| Stage III+IV | 3 (0.6) | 3 (100.0) | 0 (0.0) | |
| Cannot be determined | 12(2.5) | 8 (66.7) | 4 (33.3) |
†, includes columnar cell variant, cribriform-morular variant, solid variant, oncocytic variant, and Warthin-like variant. PTC, papillary thyroid carcinoma; IFV, infiltrative follicular variant; EFV, encapsulated follicular variant; AJCC, American Joint Committee on Cancer; SD, standard deviation; n/a, not applicable.